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INTRODUCTION
Autologous stem cell transplantation using peripheral
blood stem cells (PBSCs) is a well-established means of treat-
ing a variety of malignant conditions in adult populations;
however, the pediatric experience is less extensive [1]. Many
methods used for harvesting and transplanting PBSCs in
adults are not feasible in small children because of physiolog-
ic differences, including smaller blood volumes. The first
reported use of PBSCs for transplantation for pediatric
malignancies appeared in 1989 in which two small children
with neuroblastoma were described [2]. Watanabe et al. sub-
sequently described the kinetics of cellular recovery after
PBSC transplantation in a small number of pediatric patients
with a variety of malignant disorders [3]. Since then trans-
plant centers have reﬁned the collection and use of PBSCs
for transplantation in children and adolescents with a variety
of malignancies [4–9]. This paper outlines our experience
with peripheral stem cell harvest and transplant in 35 pedi-
atric patients with a variety of malignant diseases.
MATERIALS AND METHODS
Patients
A total of 35 patients 16 years of age underwent PBSC
harvesting and subsequent autologous transplantation for a
malignant disease at Children’s Memorial Hospital (Chica-
go, IL) between September 1992 and April 1997. All
patients were treated according to an institutional review
board–approved PBSC transplant protocol with informed
consent by the parent or guardian or the patient when age
permitted. There were 19 male and 16 female patients in
this treatment group with a median age of 6.31 years (range,
1.4–16.9 years) at the time of transplant. The median
weight was 22.2 kg (range, 8.6–111.0 kg), with 21 patients
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ABSTRACT
Thirty-five pediatric patients, 1–16 years of age (median 6.3 years), with neoplastic solid tumors (n32) or acute
leukemia (n3) underwent peripheral blood stem cell (PBSC) harvest and transplantation at Children’s Memorial
Hospital between September 1992 and April 1997. A median of four phereses were performed on each patient.
Blood samples from 34 of the 35 patients were harvested through existing double-lumen central catheters, using
either a Fenwal CS-3000 or COBE Spectra pheresis machine. The pheresis procedures were well tolerated overall.
A median of 3.7106/kg CD34 cells were infused (range, 0.2–15.5106/kg), and all patients engrafted. The median
time to an absolute neutrophil count 500/L was 13 days (range, 9–44 days) and to a platelet count 20,000/L
was 21 days (range, 9–210 days). Two patients died from transplant-related complications. Patients were discharged
from the hospital after a median of 22 days (range, 15–64 days). Twenty of the 35 patients are alive, 17 of whom
remain disease-free with a median follow-up of 1144 days. According to this study, PBSCs can be successfully har-
vested and re-infused for marrow reconstitution after myeloablative therapy in children for a variety of pediatric
malignancies with low morbidity and mortality. 
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weighing 25 kg. The group represented ten different diag-
noses, with stage 4 neuroblastoma (according to the Inter-
national Neuroblastoma Staging System [INSS]) [10] the
most frequent (14 of 35). The median time from diagnosis
to transplant was 229 days (range, 120–1680 days). Pretrans-
plant status included 26 patients in ﬁrst complete remission
or second complete remission, 3 patients in very good par-
tial remission, and 6 patients in ﬁrst or second partial remis-
sion (Table 1). All patients had received previous disease-
speciﬁc chemotherapy with or without surgery and radiation
therapy for their malignancy. Three patients (patients 19,
20, and 29) underwent a previous subablative high-dose
chemotherapy regimen with stem cell rescue as part of con-
solidation therapy before their myeloablative regimen with
PBSC rescue. All patients underwent a standard pretrans-
plant evaluation to establish their performance status.
Mobilization
Mobilization for PBSC harvesting was performed using
tumor-speciﬁc chemotherapy plus granulocyte colony-stim-
ulating factor (G-CSF) (n27), cyclophosphamide plus G-
CSF (n6), or G-CSF (10 g/kg/day) alone (n2). The
doses of G-CSF used in the chemotherapy group varied
between 5 and 10 g/kg daily, depending on the specific
treatment protocol. The timing for harvesting was based on
total white blood cell (WBC) recovery, the percentage of
monocytes after chemotherapy, or after 4-day duration of
G-CSF therapy in the patients who received no chemo-
therapy for mobilization.
PBSC harvest
The harvesting procedure was carried out in the hospi-
tal dialysis unit using either a Fenwal CS-3000 (ﬁve patients;
Baxter Healthcare, Deerfield, IL) or a COBE Spectra (30
patients, COBE BCT, Lakewood, CO), according to manu-
facturer recommendations. In those patients who had bone
marrow involvement at diagnosis, harvesting was performed
after induction of remission when the marrow was morpho-
logically normal. A portion of the patients with neuroblas-
toma had tumor contamination of peripheral blood and
bone marrow assessed by immunoﬂuorescence before har-
vesting [11]. Blood samples from 34 patients were harvested
via a double lumen Broviac or Hickman catheter, ranging in
size from 6 to 12 French (F). One patient underwent har-
vesting via a 4-F peripheral central venous catheter with
return through a peripheral intravenous catheter. Anticoag-
ulation was accomplished with acid citrate dextrose at a ratio
of 1:10–1:25, depending on the patient’s hematocrit and
platelet count. In those patients weighing 20 kg, the
pheresis machine was primed with irradiated, leuko-poor,
packed red blood cells and plasma. The target value for total
collection and transplantation was a minimum of 2.0108
mononuclear cells (MNCs) per kg of body weight.
Processing and storage
Once a single pheresis was completed, a sample was
removed for cell count, bacterial and fungal cultures, colony
assay, and immunophenotypic analysis. All procedures were
performed using sterile technique under a laminar ﬂow hood
when appropriate. Collections were soft spun to remove
excess plasma and reduce the volume. Dimethyl sulfoxide
(DMSO; Sigma, St. Louis, MO) was added as a cryoprotec-
tant at a ﬁnal concentration of 10% with a mixture of TC-
199 (70%; Gibco, Grand Island, NY) and the patient’s plas-
ma (20%). No purging was performed. Specimens were sub-
divided into 60-mL storage bags (Baxter Healthcare),
labeled, and cooled on ice. Collections were then frozen in a
controlled-rate liquid nitrogen freezer (KRYO 10, Planer,
England) at a rate of 1C per minute to –35C, then 2C per
minute to –70C, and finally placed in the liquid phase of
nitrogen at –196C.
Specimen characterization
Cell counts were performed on a Coulter JT automated
cell counter (Coulter, Miami, FL), which formed the basis
Table 1. Tumor status and outcomes
Status PFS Survival Cause of 
Pt Tumor type Pre-tx Post-tx (days) (days) death
1 Neuroblastoma CR1 CR 176 321 —
2 Neuroblastoma CR1 CR 376 850 —
3 Neuroblastoma CR1 CR 337 714 PD
4 Neuroblastoma CR1 CR 212 296 PD
5 Neuroblastoma CR1 CR 1474 1474 —
6 Neuroblastoma CR1 CR 301 337 PD
7 Neuroblastoma CR1 CR 371 420 PD
8 Neuroblastoma CR1 CR 2001 2001 —
9 Neuroblastoma VGPR CR 1085 1085 —
10 Neuroblastoma VGPR CR 1084 1084 —
11 Neuroblastoma VGPR CR 224 1434 —
12 Neuroblastoma PR1 PR 1049 1321 —
13 Neuroblastoma PR1 PR 1329 1329 —
14 Neuroblastoma CR2 CR 1823 1823 —
15 Rhabdomyosarcoma CR1 CR 542 611 PD
16 Rhabdomyosarcoma CR1 CR 292 458 PD
17 Rhabdomyosarcoma CR1 CR 204 321 PD
18 Rhabdomyosarcoma CR1 CR 1616 1616 —
19 Rhabdomyosarcoma CR1 CR 439 439 —
20 Rhabdomyosarcoma CR2 CR 329 414 PD
21 Medulloblastoma CR2 CR 232 342 PD
22 Medulloblastoma CR2 CR 489 931 —
23 Medulloblastoma CR2 CR 91 91 MSOF
24 Wilms’ tumor CR2 CR 117 132 PD
25 Wilms’ tumor CR1 CR 126 205 PD
26 Wilms’ tumor CR2 CR 1202 1202 —
27 Hodgkin’s disease PR1 CR 1370 1370 —
28 Hodgkin’s disease PR2 CR 32 32 a
29 Ewing’s sarcoma/PNET CR1 CR 987 987 —
30 Ewing’s sarcoma/PNET PR1 PR 439 439 —
31 NHL PR2 PD 30 61 PD
32 NHL CR1 CR 1907 1907 —
33 ALL CR2 CR 230 321 PD
34 ALL CR2 CR 914 914 —
35 ANLL CR1 CR 1063 1063 —
ALL, acute lymphoblastic leukemia; ANLL, acute nonlymphoblastic leukemia; 
CR, complete remission; MSOF, multisystem organ failure; NHL, non-
Hodgkin’s lymphoma; Neuroblastoma, stage 4 neuroblastoma; PD, progressive
disease; PFS, progression-free survival; PNET, peripheral neuroectodermal
tumor; PR, partial remission; Pre- or Post-tx, pre- or posttransplant; 
Pt, patient; VGPR, very good partial remission.
abronchiolitis obliterans.
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for calculating the total nucleated cell (TNC) count and
total MNC count. Flow cytometry was performed on a
FACSort (BDIS, San Jose, CA), following recommended
manufacturer procedures. Immunophenotyping was based
on the MNC population and included the assessment of the
CD45	/CD14	, CD34	/CD33	, CD34	/CD38	, and
human leukocyte antigen-DR	/CD34	 cell populations.
Antibodies used were supplied by BDIS. Colony assays were
performed using methylcellulose (Methocult, Stem Cell
Technologies, Vancouver, Canada) in 16-well culture plates
in a 5% CO2 incubator with 100% humidity and a seeding
density of 0.5106 cells/mL. Colony counts were performed
on days 7 and 14, assessing for blast colonies, colony-form-
ing units granulocyte/macrophage (CFU-GM), and burst-
forming unit-erythroid (BFU-E) by usual criteria [12]. For
quality control purposes on the day of transplantation, all of
these assays were repeated after thawing.
Conditioning regimens
There were six different ablative regimens used as con-
ditioning for transplantation in this group of patients. They
were chosen on the basis of the individual patient and the
specific malignancy being treated. The regimens included
thiotepa/cyclophosphamide (n17), thiotepa/cyclophos-
phamide/carboplatin (n10), total-body irradiation
(TBI)/VP-16/cyclophosphamide (n4), melphalan/cyclo-
phosphamide (n2), TBI/melphalan (n1), and
busulfan/cyclophosphamide/VP-16 (n1). TBI was deliv-
ered in the outpatient setting. All 35 patients received their
chemotherapeutic conditioning as inpatients.
Transplantation and supportive care
Re-infusion of stem cells was performed 36–48 hours
after completing the chemotherapeutic portion of the condi-
tioning regimen. All patients were cared for in hepa-ﬁltered,
high-ﬂow isolation rooms after receiving their stem cell infu-
sion. Cells were transported to the transplantation unit in liq-
uid nitrogen, quick-thawed in a 37C water bath, and infused
through one lumen of the central venous line by gravity, with
a ﬁlter to remove ﬁbrin clots. Patients were treated with pro-
phylactic fluconazole, acyclovir, monthly intravenous
immunoglobulin, and vancopaste mouthcare. After obtaining
central and peripheral blood cultures and urine cultures,
broad-spectrum antibiotics were begun for fever 38.5C or
hemodynamic instability. Nutrition was routinely supported
parenterally. Beginning on day 7 posttransplant, all patients
received G-CSF (n7) or GM-CSF (n28).
RESULTS
PBSC Harvest
The median number of harvests per patient was 4
(range, 1.0–9.0 harvests), with a median harvest time of 4
hours (range, 1.5–6 hours). The median total volume har-
vested was 592 cc, with a median ﬂow rate of 20 mL/min
and a median of 2 blood volumes processed (range, 0.5–5).
Median number of TNCs collected/pheresis was
0.8108/kg (range, 0.01–13108), absolute MNCs collect-
ed/pheresis was 0.4108/kg (range, 0.01–4.1), and absolute
CD34	 cells collected/pheresis was 0.5106/kg (range,
0.004–14). The median number of CFU-GM colonies at
day 14 was 50 per 0.5106 cells plated (range, 1–813), and
BFU-E colonies was 16 per 0.5106 cells plated (range,
1–301) (Table 2). All patients tolerated the collection pro-
cedures well, without need for sedation. Morbidity from
the harvesting procedure was limited to the need for trans-
fusion of platelets post-procedure. Fourteen of the 35
patients received platelets for a platelet count 20,000/L,
with a total of 27 transfusions performed out of 145 phere-
sis procedures. One patient, who was hypocalcemic before
the pheresis, received calcium supplementation. One
patient developed hypotension during one pheresis proce-
dure, which required discontinuation of the collection. The
patient recovered after a bolus of normal saline, with no
lasting sequelae.
Engraftment
All patients who received transplants engrafted. The
median time to an absolute neutrophil count (ANC)
500/L was 13 days (range, 9–44 days). The median time
to a platelet count 20,000/L was 21 days (range, 9–210
days) (Table 2). Three patients failed to achieve a platelet
count 20,000/L before day 100 posttransplant: one died
in complete remission at day 32 from bronchiolitis obliter-
ans associated with adenovirus; one died at day 91 in CR of
multisystem organ failure; and a third patient developed
idiopathic thrombocytopenia, but achieved transfusion inde-
pendence by day 105.
Engraftment kinetics were studied as a function of
TNCs per transplant (TNCs/Tx), MNCs infused per kilo-
gram (MNCs/kg), and the absolute CD34 cells per kg (ABS
CD34/kg). The time until neutrophil reconstitution and
platelet reconstitution was studied as deﬁned above. A linear
regression was first performed on the data. No significant
statistical relationship was found for ANC recovery. The p
values for the parameters were as follows: TNCs/Tx, p 
0.36; MNCs/kg, p  0.36; and ABS CD34/kg, p  0.56.
Similarly, no correlation was found for platelet reconstitu-
tion as can be seen by the following p values: TNCs/Tx, p 
0.54; MNCs/kg, p  0.83; and ABS CD34/kg, p  0.78.
Table 2. PBSC harvest and engraftment
Mean Median Range
Number of phereses 4.1 4.0 1–9
Harvesting time (hours) 4 4 1.5–6
Blood volumes processed 2 2 0.5–4.75
Flow rates (mL/min) 20 20 8–33
TNCs/kg/pheresis (1010) 1.6 0.8 0.01–13
MNCs/kg/pheresis (108) 0.6 0.4 0.01–4.1
CD34/kg/pheresis (106) 1.2 0.5 0.004–14
CFU-GM/BFU-E (day 14) 146/36 50/16 (1–813)/(1–301)
TNCs/kg infused (1010) 1.6 1.0 0.1–6.8
MNCs/kg infused (108) 2.65 2.1 0.2–7.6
CD34/kg infused (106) 4.6 3.7 0.2–15.5
ANC 500/L (days) 14.8 13 9–44
Platelets 20,000/L (days) 35 21 9–210
ANC, absolute neutrophil count; BFU-E, burst-forming unit-erythroid; 
CFU-GM, colony-forming units granulocyte/macrophage; MNCs, mononuclear
cells; TNCs, total nucleated cells.
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Additionally, a logarithmic transform was performed on
the original data. No signiﬁcant correlations were found for
either neutrophil or platelet recovery. The p values for the
neutrophil regression were p  0.27 for natural logarithm
(ln) TNCs/Tx, p  0.46 for ln MNCs/kg, and p  0.41 for
ln ABS CD34/kg. The p values for the platelet regression
were p  0.31 for ln TNCs/Tx, p  0.83 for ln MNCs/kg,
and p  0.83 for ln ABS CD34/kg.
Transplant-related morbidity was low. Mucositis was
limited to grade 1 or 2, and there were no cases of veno-
occlusive disease (VOD). There were six documented posi-
tive blood cultures: Pseudomonas (n2), E. coli (n1), Kleb-
siella (n1), Enterobacter cloacae (n1), and Candida tropicalis
(n1); all were successfully treated with appropriate antimi-
crobial therapy. One patient required amputation of her toe
for debridement of a localized Aspergillus infection, and was
subsequently treated with amphotericin B with resolution of
the infection. Of the 32 patients who survived 100 days
posttransplant, 29 were in complete remission and 3 were in
a persistent partial remission. Of the patients who died
before day 100, one died of progressive disease at day 61
after transplant; whereas the other two were in complete
remission at the time of their death, days 32 and 91, respec-
tively. At the time of this writing, 20 of 35 patients were
alive with a median follow-up of 1144 days. Seventeen of
the 20 remain disease-free. The mean length of hospital stay
from the beginning of the chemotherapeutic ablation to dis-
charge was a median 22 days (range, 15–64 days).
DISCUSSION
As PBSCs become a more widely accepted and utilized
material for autologous transplantation in children, it is
important to remember the unique aspects of this procedure
in this patient population. Patient size greatly affects both
harvesting and transplanting procedures. In particular, ade-
quate venous access is needed to ensure sufﬁcient ﬂow rates
for collection. The pediatric literature describes multiple
access devices including dialysis catheters, radial arterial
lines, femoral catheters, central venous lines, and peripheral
venous lines [4–6]. All patients but one in our study under-
went harvesting, their existing central venous catheters used
for access and return. This eliminated the need for place-
ment of a separate access device and exposure to the risks of
additional anesthesia. These catheters provided sufficient
flow rates for collection in a group of heavily treated
patients who were primarily mobilized with treatment-spe-
ciﬁc chemotherapy plus cytokines (n27 [of 35]).
The size of the patient is also important with respect to
the volume of the graft to be infused. To limit the infusions
to a reasonable total volume and to allow infusion in a single
session, the harvest collections were soft-spun to reduce the
volume. This also facilitated storage by decreasing the total
number of bags needed. In addition, a smaller total volume
reduces the amount of DMSO needed for cryoprotection,
which in turn reduces the risk of toxicity.
Several studies have shown by immunocytologic means
or long-term culture that PBSC harvests in patients with
solid tumors may be contaminated with viable tumor cells
when the marrow appears morphologically normal [13–15].
However, the clinical signiﬁcance of circulating tumor cells
relative to the risk of relapse upon re-infusion at the time of
transplant is not known. While this study was not designed
to evaluate this question, our group and others have shown
that there are fewer tumor cells present in PBSC collections
from solid tumor patients than in marrow analyzed at simi-
lar points in therapy [11,16]. In fact, in patients with stage 4
neuroblastoma (INSS), peripheral blood has less tumor cell
contamination than does bone marrow that is purged by
either positive or negative selection techniques [17]. Recov-
ery of hematopoietic function after myeloablative therapy
has been well documented as faster with PBSCs as com-
pared with bone marrow–derived stem cells, especially with
regard to platelets [18]. Engraftment in our group of
patients is in accordance with that reported by other authors
[4,5]. One patient (#17) had delayed engraftment but was
treated throughout the transplant course with ganciclovir
for an active cytomegalovirus infection, which was acquired
before transplantation. The transplanted cell dose does play
a role in the speed of reconstitution in the autologous trans-
plant setting. The median TNCs/kg infused was
1.01010/kg, with a range of 0.1–6.81010/kg, which is
comparable with that reported in the pediatric literature
[19,20]. In the adult literature, the suspected minimum
CD34	 cell dose needed is approximately 1106/kg [1].
The median infused CD34	 cell dose/kg given in these
patients was higher but, as shown in the Results section,
there was no correlation between any measurement of cell
dose and time to engraftment.
Morbidity was limited for both the harvesting and the
transplanting procedures. Only one patient suffered a
significant complication from the harvesting procedure. A
post-harvest platelet transfusion was performed after only
19% of pheresis procedures—a low rate given that most
patients underwent harvesting in the recovery phase after
chemotherapy. The conditioning regimens were well toler-
ated without limiting toxicities. The absence of VOD is
significant, although the incidence of this complication in
autologous stem cell transplant is lower than that described
in the allogeneic setting. In our series, the lack of VOD may
be due to the small numbers of patients who received TBI
(n5) or busulfan (n1), both of which have been linked to
an increased incidence of VOD [21]. Transplant-related
mortality was low, with two deaths attributable to complica-
tions in the immediate 100 days posttransplant. Overall out-
comes were quite good despite a patient population heavily
weighted with stage 4 neuroblastoma (INSS), for which the
progression-free survival after intensive chemotherapy with
autologous transplantation in various studies ranges from 25
to 50% [22–24]. Clearly, the length of follow-up for this
series of patients is still relatively short, and ﬁrm conclusions
regarding overall efﬁcacy must be reserved.
Length of hospital stay and total costs have both
become signiﬁcant factors as they relate to expensive proce-
dures like transplantation. The median length of stay (LOS)
for this group of patients was only 22 days. Working to
ensure quality care while maintaining control over total
costs is an ongoing challenge. Decreasing LOS may certain-
ly have a major impact on decreasing overall costs.
Our experience with PBSC harvesting and transplanta-
tion demonstrates the feasibility of this procedure as a
modality for treating young children with a variety of malig-
PR Haut et al.
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nancies with low morbidity and mortality. The challenges
for the future include CD34 positive selection for solid
tumor patients to further reduce the likelihood of tumor
contamination, continued refinement of mobilization and
harvesting procedures, and better defining those pediatric
patients who would optimally beneﬁt from autologous stem
cell transplantation.
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